Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Articles
Articles
Cybersecurity Framework Implementation Guide Helps Healthcare Organizations Manage Risk
Cybersecurity
April 2023, Vol 14, No 2
The Health Sector Coordinating Council Cybersecurity Working Group and the US Department of Health and Human Services jointly released a guide to help the public and private healthcare sectors align their cybersecurity programs with the National Institute of Standards Technology Cybersecurity Framework.
Read More
FDA Updates Mammography Regulations to Require Reporting of Breast Density Information
Women's Health
,
Breast Cancer
,
Health Policy
April 2023, Vol 14, No 2
The FDA has issued a final rule intended to ensure patients are better informed about their breast tissue density when undergoing mammography. The rule updates regulations first issued in the 1990s under the Mammography Quality Standards Act to oversee mammography facilities and improve breast cancer testing.
Read More
Researchers Predict Rise in the Incidence of Cholangiocarcinoma Over the Next 10 Years
Cholangiocarcinoma
April 2023, Vol 14, No 2
Cholangiocarcinoma (CCA), a rare and aggressive form of cancer, has seen a steady increase in incidence in the United States, with a predominant increase in intrahepatic CCA, from 2001 to 2017, according to a recent epidemiological study.
Read More
Study Reveals Alarming Disparities in Opioid Access Among Patients with Cancer at End of Life
Disparities in Cancer Care
April 2023, Vol 14, No 2
Older Black and Hispanic patients with advanced cancer are less likely than White patients to receive opioid medications for pain relief in the last weeks of life, according to the results of a recent study published in the
Journal of Clinical Oncology
.
Read More
Why AVBCC?
AVBCC
Videos
Join Luh, MD, Clinical Radiation Oncologist, Providence St. Joseph Hospital, shares why he thinks AVBCC is great.
Read More
Navigating Care Programs in the Post-OCM era
Webinars
Videos
Since OCM ended in June of 2022, oncology practice leaders have navigated complex decisions about how to offer patients high-quality, value-driven cancer care and in which reimbursement programs they will participate.
Read More
Tukysa, in Combination with Trastuzumab, Now FDA Approved for HER2-Positive, Unresectable or Metastatic Colorectal Cancer
FDA Approvals, News & Updates
,
Colorectal Cancer
February 2023, Vol 14, No 1
On
January 19, 2023
, the FDA accelerated the approval of tucatinib (Tukysa; Seagen), a Bruton tyrosine kinase inhibitor, in combination with trastuzumab (Herceptin), a HER2/
neu
receptor agonist, for the treatment of
RAS
wild-type,
HER2
-positive, unresectable or metastatic colorectal cancer (CRC) that progressed after fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies.
Read More
Zanubrutinib Superior to Ibrutinib in Patients with Relapsed or Refractory CLL/SLL
By
Phoebe Starr
ASH Highlights
,
Leukemia
,
Lymphoma
February 2023, Vol 14, No 1
A head-to-head phase 3 clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) has found that zanubrutinib (Brukinsa), a next-generation Bruton tyrosine kinase (BTK) inhibitor, is more effective at preventing disease progression and better tolerated than ibrutinib (Imbruvica), a first-generation BTK inhibitor that has been the current standard of care for this population of patients.
Read More
Survey Results Provide Insights into Biosimilar Use at Cancer Centers
By
Wayne Kuznar
Biosimilars
,
ASCO 2022 Highlights
February 2023, Vol 14, No 1
Results from a survey of cancer centers revealed that 66% of responding institutions had a biosimilar interchangeability policy in place, but barriers to adoption remain an issue.
Read More
Ribociclib plus Endocrine Regimen Outperforms Combination Chemotherapy in Advanced Breast Cancer
By
Phoebe Starr
SABCS Highlights
,
Breast Cancer
February 2023, Vol 14, No 1
Patients with hormone receptor (HR)-positive,
HER2
-negative advanced breast cancer, including those with visceral crises, treated with the CDK4/6 inhibitor ribociclib (Kisqali) plus endocrine therapy had a significantly longer progression-free survival (PFS) and fewer adverse events (AEs) compared with those treated with combination chemotherapy, according to results from the phase 2 RIGHT Choice trial.
Read More
Page 9 of 338
4
5
6
7
8
9
10
11
12
13
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma